Positioning of lopinavir/ritonavir in antiretroviral treatment schemes
Copyright © 2014 Elsevier España, S.L.U. All rights reserved..
Lopinavir/ritonavir (LPV/r) was approved for use in the treatment of human immunodeficiency virus (HIV) infection in 2001 and is the protease inhibitor that has been most widely studied in clinical trials. Despite the time interval since its approval, all the evidence accumulated in the last 14 years indicates that LPV/r continues to occupy an important position among antiretroviral drugs. Firstly, LPV/r plus 2 nucleoside/nucleotide analogs is still considered a good option for initial antiretroviral therapy (ART). Secondly, numerous studies have evaluated the efficacy and safety of new initial ART strategies based on LPV/r in dual therapy. The results obtained suggest that LPV/r plus lamivudine (3TC) or raltegravir can be as effective in initial ART as standard triple therapy and justify their consideration as alternative regimens in this scenario. Thirdly, LPV/r is a pioneer drug, as well as being the agent with the largest amount of evidence from clinical trials on simplification to monotherapy (LPV/r) or dual therapy (LPV/r + 3TC). Lastly, LPV/r is highly useful is special situations. It has a low risk of liver toxicity in patients with chronic liver disease, its use is preferred in the treatment of patients with HIV-2, and it is safe and effective in preventing vertical HIV transmission.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 Suppl 3 |
|---|---|
| Enthalten in: |
Enfermedades infecciosas y microbiologia clinica - 32 Suppl 3(2014) vom: 15. Nov., Seite 31-4 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Posicionamiento de lopinavir/ritonavir en los esquemas de la terapia antirretroviral |
|---|
| Beteiligte Personen: |
Camacho, Ángela [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.10.2016 Date Revised 21.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0213-005X(14)70166-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM244907218 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM244907218 | ||
| 003 | DE-627 | ||
| 005 | 20231224135716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/S0213-005X(14)70166-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0816.xml |
| 035 | |a (DE-627)NLM244907218 | ||
| 035 | |a (NLM)25542874 | ||
| 035 | |a (PII)S0213-005X(14)70166-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Camacho, Ángela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Positioning of lopinavir/ritonavir in antiretroviral treatment schemes |
| 246 | 3 | 3 | |a Posicionamiento de lopinavir/ritonavir en los esquemas de la terapia antirretroviral |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2016 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2014 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Lopinavir/ritonavir (LPV/r) was approved for use in the treatment of human immunodeficiency virus (HIV) infection in 2001 and is the protease inhibitor that has been most widely studied in clinical trials. Despite the time interval since its approval, all the evidence accumulated in the last 14 years indicates that LPV/r continues to occupy an important position among antiretroviral drugs. Firstly, LPV/r plus 2 nucleoside/nucleotide analogs is still considered a good option for initial antiretroviral therapy (ART). Secondly, numerous studies have evaluated the efficacy and safety of new initial ART strategies based on LPV/r in dual therapy. The results obtained suggest that LPV/r plus lamivudine (3TC) or raltegravir can be as effective in initial ART as standard triple therapy and justify their consideration as alternative regimens in this scenario. Thirdly, LPV/r is a pioneer drug, as well as being the agent with the largest amount of evidence from clinical trials on simplification to monotherapy (LPV/r) or dual therapy (LPV/r + 3TC). Lastly, LPV/r is highly useful is special situations. It has a low risk of liver toxicity in patients with chronic liver disease, its use is preferred in the treatment of patients with HIV-2, and it is safe and effective in preventing vertical HIV transmission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiretroviral therapy | |
| 650 | 4 | |a HIV infection | |
| 650 | 4 | |a Infección por el VIH | |
| 650 | 4 | |a Lopinavir/ritonavir | |
| 650 | 4 | |a Tratamiento antirretroviral | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a HIV Integrase Inhibitors |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Reverse Transcriptase Inhibitors |2 NLM | |
| 650 | 7 | |a lopinavir-ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Rivero, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Enfermedades infecciosas y microbiologia clinica |d 1993 |g 32 Suppl 3(2014) vom: 15. Nov., Seite 31-4 |w (DE-627)NLM01273425X |x 1578-1852 |7 nnns |
| 773 | 1 | 8 | |g volume:32 Suppl 3 |g year:2014 |g day:15 |g month:11 |g pages:31-4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0213-005X(14)70166-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 Suppl 3 |j 2014 |b 15 |c 11 |h 31-4 | ||